As in vivo lentiviral therapies advance from research to clinical reality, developers face increasing pressure to deliver scalable, high-purity vector manufacturing processes that support regulatory readiness and commercial viability. Higher dosing requirements, tighter impurity specifications, and the need for robust batch consistency are reshaping expectations for viral vector production.
In this GENcast podcast, experts from SK pharmteco discuss manufacturing strategies that help overcome these challenges and accelerate the path to the clinic. Learn how optimized lentiviral vector production processes can improve purity profiles, enhance scalability, and support reproducible manufacturing performance across development stages.
What You’ll Learn
- Key manufacturing considerations for emerging in vivo lentiviral therapies
- Approaches to improve vector purity and reduce process-related impurities
- Strategies for scalable production and batch-to-batch consistency
- Best practices to support clinical readiness and future commercialization
- How integrated CDMO expertise can streamline development timelines
Watch the Podcast
Discover how advanced manufacturing strategies can help de-risk lentiviral vector development and prepare your therapy for clinical and commercial success.
Featured Experts
- Tatiana Nanda, PhD – CTO, Cell and Gene Therapy, SK pharmteco
- Mardhani Aparajithan – Director, Manufacturing Science & Technology, SK pharmteco